SLS
Sellas Life Sciences Group IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.45B
P/E Ratio
—
EPS
$-0.23
Beta
2.24
52W High
$9.10
52W Low
$1.39
50-Day MA
$5.29
200-Day MA
$3.32
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 900,000 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -43.60% |
| Return on Assets | -25.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.46 |
| Price-to-Book | 13.47 |
| Price-to-Sales (TTM) | 26.90 |
| EV/Revenue | 20.84 |
| EV/EBITDA | -1.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -82.50% |
| Shares Outstanding | $186.03M |
| Float | $185.23M |
| % Insiders | 0.43% |
| % Institutions | 29.22% |
Historical Volatility
HV 10-Day
177.06%
HV 20-Day
134.23%
HV 30-Day
115.77%
HV 60-Day
110.57%
HV Rank
88.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($10.00 target)
1
Strong Buy1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026